Osimertinib(Tagrisso)

Launch ofthe patient support program for the FLAURA2 indication, opening on October 1, 2025. The indication covered by this program: TAGRISSO in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative treatment) or metastatic NSCLC carrying a deletion in exon 19 or a substitution mutation … Read more

Scemblix® (asciminib) is now available for patients with newly diagnosed and previously treated chronic myeloid leukemia (CML) . Scemblix® is the first drug to demonstrate superior efficacy and a favorable safety and tolerability profile in a Phase III trial, compared to all standards of care. Contact Novartis for more information on the patient support program.